Yoshiki Negi1, Kozo Kuribayashi2,3, Norihiko Funaguchi4, Hiroshi Doi5, Koji Mikami1, Toshiyuki Minami1, Teruhisa Takuwa6, Takashi Yokoi3, Seiki Hasegawa6, Takashi Kijima1,3. 1. Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan. 2. Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan kuririn@hyo-med.ac.jp. 3. Department of Thoracic Oncology, Hyogo College of Medicine, Hyogo, Japan. 4. Department of Respiratory Medicine, Murakami Memorial Hospital, Asahi University, Hyogo, Japan. 5. Department of Radiology, Hyogo College of Medicine, Hyogo, Japan. 6. Department of Thoracic Surgery, Hyogo College of Medicine, Hyogo, Japan.
Abstract
BACKGROUND/AIM: A strategy for improving survival of malignant pleural mesothelioma (MPM) patients is earlier diagnosis paired with earlier stage implementation of therapeutic interventions. This study aimed to determine the clinical signs of early-stage MPM to aid an earlier diagnosis and earlier-stage intervention. MATERIALS AND METHODS: Out of the 72 cases in our institution, 40 cases with 18F-FDG-PET/CT-negative MPM were retrospectively identified between 2007 and 2015. Overall survival rates were determined and compared with pathological features, histology, and treatment. RESULTS: The biphasic histological type of early-stage MPM was characterized by poor prognosis (p=0.0006). Additionally, the cytology-negative group (Class III and below) showed significantly shorter survival times (p=0.0290). There was no significant difference in survival between patients who received pleurectomy and those who received chemotherapy only (p=0.6991). Bimodal therapy resulted in a longer survival rate than trimodal therapy. CONCLUSION: In early-stage PET-negative MPM cases, biphasic histology and pleural effusion of Class III and below correlated with a poor prognosis. Surgical treatment using pleurectomy/decortication resulted in higher patient survival outcomes than therapy with extrapleural pneumonectomy. Copyright
BACKGROUND/AIM: A strategy for improving survival of malignant pleural mesothelioma (MPM) patients is earlier diagnosis paired with earlier stage implementation of therapeutic interventions. This study aimed to determine the clinical signs of early-stage MPM to aid an earlier diagnosis and earlier-stage intervention. MATERIALS AND METHODS: Out of the 72 cases in our institution, 40 cases with 18F-FDG-PET/CT-negative MPM were retrospectively identified between 2007 and 2015. Overall survival rates were determined and compared with pathological features, histology, and treatment. RESULTS: The biphasic histological type of early-stage MPM was characterized by poor prognosis (p=0.0006). Additionally, the cytology-negative group (Class III and below) showed significantly shorter survival times (p=0.0290). There was no significant difference in survival between patients who received pleurectomy and those who received chemotherapy only (p=0.6991). Bimodal therapy resulted in a longer survival rate than trimodal therapy. CONCLUSION: In early-stage PET-negative MPM cases, biphasic histology and pleural effusion of Class III and below correlated with a poor prognosis. Surgical treatment using pleurectomy/decortication resulted in higher patient survival outcomes than therapy with extrapleural pneumonectomy. Copyright
Authors: D J Sugarbaker; R M Flores; M T Jaklitsch; W G Richards; G M Strauss; J M Corson; M M DeCamp; S J Swanson; R Bueno; J M Lukanich; E H Baldini; S J Mentzer Journal: J Thorac Cardiovasc Surg Date: 1999-01 Impact factor: 5.209
Authors: M E R O'Brien; D Watkins; C Ryan; K Priest; C Corbishley; A Norton; S Ashley; N Rowell; R Sayer Journal: Ann Oncol Date: 2005-11-29 Impact factor: 32.976
Authors: V W Rusch; K Rosenzweig; E Venkatraman; L Leon; A Raben; L Harrison; M S Bains; R J Downey; R J Ginsberg Journal: J Thorac Cardiovasc Surg Date: 2001-10 Impact factor: 5.209
Authors: A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Péchoux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder Journal: Eur Respir J Date: 2009-08-28 Impact factor: 16.671
Authors: Marc de Perrot; Ronald Feld; B C John Cho; Andrea Bezjak; Masaki Anraku; Ronald Burkes; Heidi Roberts; Ming S Tsao; Natasha Leighl; Shaf Keshavjee; Michael R Johnston Journal: J Clin Oncol Date: 2009-02-17 Impact factor: 44.544
Authors: Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto Journal: Lancet Oncol Date: 2011-06-30 Impact factor: 41.316
Authors: Laura Saracino; Chandra Bortolotto; Stefano Tomaselli; Elia Fraolini; Matteo Bosio; Giulia Accordino; Francesco Agustoni; David M Abbott; Emma Pozzi; Dimitrios Eleftheriou; Patrizia Morbini; Pietro Rinaldi; Cristiano Primiceri; Andrea Lancia; Patrizia Comoli; Andrea R Filippi; Giulia M Stella Journal: BMC Cancer Date: 2021-07-01 Impact factor: 4.430